eSwatini king claims Covid-19 recovery after Taiwan sent medication
eSwatini's King Mswati III said he had recovered from Covid-19 after Taiwan President Tsai Ing-wen sent antiviral medication to help him.
The small southern African country, an absolute monarchy formerly known as Swaziland, is Taiwan's only remaining diplomatic ally on the continent, and Taipei has provided large amounts of economic and other aid.
In a speech on Friday, the king said while the country awaited the arrival of vaccines, there was an antiviral drug that could be used to treat the illness, which he did not name.
He said he had tested positive “for a couple of days” in the first week of January, but was now negative.
“I am grateful to the president of the Republic of China on Taiwan for sending through this medication to treat me,” he said, using the island's formal name in the speech posted on the eSwatini government's official Twitter account.
Taiwan Foreign Ministry spokesperson Joanne Ou said that upon hearing the king was infected, Tsai arranged medical assistance for him.
“The Ministry of Foreign Affairs is gratified to hear of the eSwatini king's successful recovery under the joint care of Taiwanese and eSwatini medical staff,” she said.
The king could have been referring to Gilead Sciences Inc's antiviral drug remdesivir, which was conditionally approved in Europe in July for treating Covid-19 in adults and adolescents with pneumonia requiring oxygen support.
Taiwan also provisionally approved its use last year.
Using the slogan “Taiwan can help,” the government has been keen to showcase its assistance to other countries during the pandemic, donating face masks and other supplies.
China claims Taiwan as its own territory with no right to state-to-state ties. Only 14 countries now officially recognise the island's government.
eSwatini has recorded almost 17,000 infections of the coronavirus and 644 Covid-19 deaths.
Prime Minister Ambrose Dlamini died in a South African hospital in December after testing positive for Covid-19.
Would you like to comment on this article or view other readers' comments? Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.